Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E15.88 EPS (ttm)16.91 Insider Own0.10% Shs Outstand216.42M Perf Week-3.36%
Market Cap58.12B Forward P/E12.02 EPS next Y22.35 Insider Trans-6.75% Shs Float215.33M Perf Month-6.95%
Income3.70B PEG2.48 EPS next Q4.99 Inst Own89.40% Short Float1.26% Perf Quarter-7.76%
Sales11.45B P/S5.08 EPS this Y10.30% Inst Trans-0.88% Short Ratio1.61 Perf Half Y-14.62%
Book/sh56.05 P/B4.79 EPS next Y6.70% ROA17.00% Target Price317.43 Perf Year5.65%
Cash/sh22.62 P/C11.87 EPS next 5Y6.39% ROE32.20% 52W Range223.02 - 333.65 Perf YTD-5.31%
Dividend- P/FCF15.31 EPS past 5Y27.40% ROI21.00% 52W High-19.36% Beta0.79
Dividend %- Quick Ratio2.30 Sales past 5Y17.80% Gross Margin87.10% 52W Low20.64% ATR5.88
Employees7400 Current Ratio2.60 Sales Q/Q1.20% Oper. Margin45.00% RSI (14)33.26 Volatility1.78% 1.85%
OptionableYes Debt/Eq0.54 EPS Q/Q-20.60% Profit Margin32.30% Rel Volume0.86 Prev Close268.53
ShortableYes LT Debt/Eq0.54 EarningsApr 27 BMO Payout0.00% Avg Volume1.69M Price269.06
Recom2.20 SMA20-5.38% SMA50-4.41% SMA200-6.71% Volume1,445,198 Change0.20%
Mar-16-17Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-16-17Downgrade Leerink Partners Outperform → Mkt Perform
Mar-02-17Initiated Instinet Buy $345
Feb-07-17Upgrade Citigroup Neutral → Buy
Dec-29-16Reiterated Raymond James Strong Buy $375 → $386
Dec-09-16Reiterated Stifel Hold $291 → $298
Nov-08-16Initiated Mizuho Buy $290
Nov-07-16Upgrade Piper Jaffray Neutral → Overweight
Nov-07-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-06-16Downgrade Jefferies Buy → Hold
Jun-29-16Initiated Bernstein Outperform
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Mar-29-17 05:43PM  Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis at Investopedia
04:31PM  Roche Multiple Sclerosis Drug OK Bittersweet For Beleaguered Biogen
09:26AM  U.S. approves Roche drug that targets severe form of MS Reuters
05:40AM  UPDATE 2-Roche MS drug Ocrevus approved by FDA after 3-month delay Reuters
Mar-28-17 08:45PM  Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen
09:07AM  Could International Laggards Come Out as Winners?
07:30AM  Biogen to Present Data at the 13th International Conference on Alzheimers and Parkinsons Diseases Business Wire
Mar-27-17 04:01PM  Biogen to Report First Quarter 2017 Financial Results on April 25, 2017 Business Wire
10:30AM  Short Interest Pulls Back in Major Biotechs
Mar-22-17 03:10PM  Cytokinetics SMA Drug Did Well in Early Study at Investopedia
12:53PM  Could Biogen Spinoff Bleed This Biotech In Hemophilia?
10:37AM  Recent Developments for Ionis Pharmaceuticals
08:33AM  Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
07:37AM  A Look at Ionis Pharmaceuticals Spinraza
12:07AM  [$$] Two Cheers for Biogens Court Victory at The Wall Street Journal
Mar-21-17 04:43PM  Biogen Wins Tecfidera Patent Case at Investopedia
04:04PM  Biogen Stock Pops After Judge Upholds Critical Drug Patent
02:13PM  Biogen wins patent decision
01:44PM  Biogen: Did Someone Say Biotech Stocks are Falling? at
12:52PM  [$$] Two Cheers for Biogen's Court Victory at The Wall Street Journal
12:26PM  Biogen wins ruling in Tecfidera IP case; shares rise
12:05PM  Understanding Ionis Pharmaceuticals 2016 Revenue Stream
11:45AM  Biogen prevails in dispute over key Tecfidera patent at
09:25AM  3 Biotech Stocks That Are Broker Favorites
09:07AM  Better Buy: Ionis Pharmaceuticals, Inc. vs. Juno Therapeutics at Motley Fool
08:17AM  Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : March 21, 2017
Mar-20-17 04:24AM  European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details
03:00AM  European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade
Mar-17-17 05:44PM  Week in Review: Stocks Post Small Gains After Fed Pulls Trigger on Third Hike Since Crisis
11:44AM  AveXis Inc Stock Is Spiking Again Today -- Here's Why at Motley Fool
10:29AM  Get Ready For A Slew of Data As Weekend Nears
10:25AM  AveXis Reports Positive Data for SMA Gene Therapy at Investopedia
07:39AM  Why Did the Healthcare Sector Fall on March 16?
Mar-16-17 04:24PM  US STOCKS-Wall St slips with healthcare stocks, Nasdaq flat
04:24PM  The Biggest Loser: Biogen Tumbles 4.7% at
04:05PM  Biogen Dives As Takeover Buzz Fades, Drugs Hit Snags
03:12PM  Stock market pares post-Fed bounce as health care, utilities slump at MarketWatch
02:32PM  Biogen, LendingClub, IBM, and More: Heres What Analysts Had to Say About These Five Stocks at Insider Monkey
12:58PM  US STOCKS-Wall St edges down as healthcare stocks hit by budget plan
12:13PM  Cramer: Confusion Reigns in This Market
12:08PM  Biogen stock drops 5.5% after downgrades at Morgan Stanley, Leerink at MarketWatch
11:32AM  US STOCKS-Wall St slightly lower as healthcare stocks weigh
11:25AM  Biogen: Double Trouble? at
10:41AM  Biogen's Catalysts May Be Waning; Leerink Downgrades To Market Perform
10:06AM  Biogen shares drop after Morgan Stanley downgrade; rest of biotech also dragged lower at CNBC
09:32AM  Morgan Stanley Takes A Breather On Biogen, Downgrades Stock
09:15AM  Analysts' Actions -- Liberty Global, RPM International, TJX, Biogen and More
07:00AM  Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development Business Wire
Mar-13-17 04:39PM  Biogen Spinoff Downgraded On Mounting Roche, Shire Rivalry
02:08PM  Biotech stocks are turning bullishhere's how to profit
12:51PM  Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears
09:40AM  Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise
Mar-10-17 01:12PM  AbbVie Stock Upgraded: What You Need to Know at Motley Fool
08:00AM  Biogen Spinoff Takes Flight With Focus On Hemophilia Drugs
Mar-09-17 12:38PM  3 Biotech Stocks to Buy Nowand 1 to Dump ASAP at
Mar-08-17 12:10PM  Biogen, Inc. :BIIB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 8, 2017
11:08AM  Pharma says high prices fund drug development. This study says otherwise at MarketWatch
09:40AM  Biogen loses another top executive as tech guru departs at
Mar-07-17 04:40PM  Biogen Tech EVP Andi Karaboutis Leaves Company at The Wall Street Journal
04:22PM  5 Things Biogen's CEO Just Said That You Don't Want to Miss at Motley Fool
Mar-06-17 02:35PM  Jeff Auxier Invests in Gilead, Wells Fargo, Apple
01:18PM  Weekly CEO Buys Highlights
09:28AM  Inovio (INO): What's in the Cards this Earnings Season?
09:21AM  4 Things Alkermes Wants Investors to Know at Motley Fool
02:16AM  Israel's BrainStorm names Biogen senior executive Kern as COO Reuters
Mar-04-17 07:25PM  Icahn's (Potential) Move Into Biotech
Mar-02-17 08:42AM  Coverage initiated on Biogen by Instinet
12:37AM  Drug Companies Block Shareholder Votes on Price Transparency Proposals at The Wall Street Journal
Mar-01-17 05:07PM  [$$] Drug Companies Block Shareholders' Voting on Price Transparency at The Wall Street Journal
03:56PM  Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money at Motley Fool
01:24PM  Investors have stopped believing Trumps drug price threats at MarketWatch
10:37AM  Regeneron Could See a Modest Rise in Net Profit Margins in 2017
09:30AM  The Zacks Analyst Blog Highlights: AT&T, Visa, Biogen, Tesla and PG&E
07:30AM  [$$] Gormley's Take: With Biotech Talent In Demand, CEO Takes Helm at Two Companies at The Wall Street Journal
Feb-28-17 04:01PM  Biogen to Present at the Cowen & Company 37th Annual Health Care Conference Business Wire
02:10PM  At rare disease panel, ex-FDA new drug head preaches evidence over empathy at
12:12PM  Roche Attempts New Trial for Alzheimer's at Investopedia
11:40AM  Top Research Reports for February 28, 2017
08:30AM  Accera's Alzheimer's trial fails, in yet another setback for disease Reuters
07:37AM  Understanding Alexions Profit Margin Trend in 2017
Feb-27-17 09:22PM  After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B
01:22PM  Rob Citrones Discovery Capital Management Grows Bullish on Energy, Airline and Healthcare Stocks at Insider Monkey
01:21PM  Better Buy: Biogen Inc. vs. Gilead Sciences Inc. at Motley Fool
07:15AM  Biogen alums team up to launch Waltham biotech, with backing from Henri Termeer at
Feb-24-17 07:35AM  Ring the Register With These Upcoming Spinoffs
Feb-23-17 05:06PM  Teva Is Expected to See a Fall in Its Profit Margins in 2017
08:02AM  Here's Why Celgene's Latest Drug Is So Exciting at Motley Fool
Feb-22-17 09:15AM  Did Biogen Inc. Shoot Itself in the Foot? at Motley Fool
Feb-21-17 03:40PM  Top pharma lobbyist casts Biogen as the anti-Shkreli during drug price Q&A at
Feb-20-17 10:30AM  Celgene MS Drug Reports Positive Phase 3 Data at Investopedia
08:24AM  3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter at Motley Fool
07:37AM  This Keeps Driving Sanofis Growth
07:36AM  Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment
Feb-19-17 11:41AM  Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands? at Motley Fool
Feb-16-17 09:40PM  Shkreli defends drug prices, spars with protesters at heated UMass Boston event at
09:37PM  Tesaro sees a $5B market opportunity for its cancer drug at
09:27AM  Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
Feb-15-17 07:34PM  Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next? at Motley Fool
05:29PM  Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference Business Wire
04:18PM  Merck's Alzheimer's Drug Fails; Are Biogen, Roche, AstraZeneca Next?
Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The company's Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkin's lymphoma; and Aducanumab and E2609 for Alzheimer's disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The company's Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clancy Paul JExecutive VP and CFOMar 13Sale291.559,8912,883,72120,705Mar 14 07:32 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.004810718Mar 03 06:07 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratMar 01Sale290.07973282,2389,041Mar 03 06:02 PM
Clancy Paul JExecutive VP and CFOFeb 28Option Exercise0.006,780031,948Mar 02 05:24 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 28Option Exercise0.004,785010,398Mar 02 05:22 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 28Option Exercise0.005,559036,024Mar 02 05:20 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 28Option Exercise0.0068104,508Mar 02 05:18 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffFeb 28Option Exercise0.002,06409,237Mar 02 05:16 PM
DiPietro KennethEVP Human ResourcesFeb 28Option Exercise0.005,69608,260Mar 02 05:12 PM
Vounatsos MichelChief Executive OfficerFeb 27Buy285.391,333380,4251,434Mar 01 04:18 PM
PANGIA ROBERT WDirectorJan 09Option Exercise52.225,450284,59922,078Jan 10 04:15 PM
PANGIA ROBERT WDirectorJan 09Sale295.395,4501,609,87616,628Jan 10 04:15 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffDec 01Sale296.534814,2337,360Dec 05 04:34 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 04Sale311.9426281,7287,579Oct 05 04:24 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 03Sale313.00380118,9407,841Oct 04 05:02 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 01Option Exercise0.001,98209,154Oct 04 05:02 PM
DORSA CAROLINEDirectorSep 22Option Exercise53.6427,5701,478,85544,663Sep 26 04:24 PM
DORSA CAROLINEDirectorSep 22Sale314.0027,5708,656,98017,093Sep 26 04:24 PM
SCANGOS GEORGE AChief Executive OfficerJul 21Sale280.0015743,96054,779Jul 22 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 06Sale290.00555160,9502,402Jun 07 04:09 PM
SCANGOS GEORGE AChief Executive OfficerJun 03Sale290.00842244,18054,936Jun 06 08:14 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 02Option Exercise0.001,64303,491Jun 06 08:48 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale287.97487140,24155,778Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 31Sale290.003,368976,72056,265Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 25Sale280.0015743,96059,633May 27 08:59 AM
SCANGOS GEORGE AChief Executive OfficerMay 02Sale274.74487133,79859,790May 04 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Apr 06Sale275.0010228,0501,848Apr 07 05:03 PM
SCANGOS GEORGE AChief Executive OfficerApr 06Sale280.0015743,96060,277Apr 07 05:01 PM
Artavanis-Tsakonas SpyridonEVP, Chief Scientific OfficerApr 02Option Exercise0.0097503,609Apr 05 05:06 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale258.83487126,05060,434Apr 05 05:02 PM